Cargando…
Therapeutic Perspectives of CD26 Inhibitors in Imune-Mediated Diseases
The enzymatic activity of CD26/DPP4 (dipeptidyl peptidase 4/DPP4) is highlighted in multiple studies to play a vital role in glucose metabolism by cleaving and inactivating the incretins glucagon-like peptide-1 (GLP) and gastric inhibitory protein (GIP). A large number of studies demonstrate that CD...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9321265/ https://www.ncbi.nlm.nih.gov/pubmed/35889373 http://dx.doi.org/10.3390/molecules27144498 |
_version_ | 1784756000060866560 |
---|---|
author | Hu, Xiaopeng Wang, Xisheng Xue, Xingkui |
author_facet | Hu, Xiaopeng Wang, Xisheng Xue, Xingkui |
author_sort | Hu, Xiaopeng |
collection | PubMed |
description | The enzymatic activity of CD26/DPP4 (dipeptidyl peptidase 4/DPP4) is highlighted in multiple studies to play a vital role in glucose metabolism by cleaving and inactivating the incretins glucagon-like peptide-1 (GLP) and gastric inhibitory protein (GIP). A large number of studies demonstrate that CD26 also plays an integral role in the immune system, particularly in T cell activation. CD26 is extensively expressed in immune cells, such as T cells, B cells, NK cells, dendritic cells, and macrophages. The enzymatic activity of CD26 cleaves and regulates numerous chomokines and cytokines. CD26 inhibitors have been widely used for the treatment of diabetes mellitus, while it is still under investigation as a therapy for immune-mediated diseases. In addition, CD26’s involvement in cancer immunology was also described. The review aims to summarize the therapeutic effects of CD26 inhibitors on immune-mediated diseases, as well as the mechanisms that underpin them. |
format | Online Article Text |
id | pubmed-9321265 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-93212652022-07-27 Therapeutic Perspectives of CD26 Inhibitors in Imune-Mediated Diseases Hu, Xiaopeng Wang, Xisheng Xue, Xingkui Molecules Review The enzymatic activity of CD26/DPP4 (dipeptidyl peptidase 4/DPP4) is highlighted in multiple studies to play a vital role in glucose metabolism by cleaving and inactivating the incretins glucagon-like peptide-1 (GLP) and gastric inhibitory protein (GIP). A large number of studies demonstrate that CD26 also plays an integral role in the immune system, particularly in T cell activation. CD26 is extensively expressed in immune cells, such as T cells, B cells, NK cells, dendritic cells, and macrophages. The enzymatic activity of CD26 cleaves and regulates numerous chomokines and cytokines. CD26 inhibitors have been widely used for the treatment of diabetes mellitus, while it is still under investigation as a therapy for immune-mediated diseases. In addition, CD26’s involvement in cancer immunology was also described. The review aims to summarize the therapeutic effects of CD26 inhibitors on immune-mediated diseases, as well as the mechanisms that underpin them. MDPI 2022-07-14 /pmc/articles/PMC9321265/ /pubmed/35889373 http://dx.doi.org/10.3390/molecules27144498 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Hu, Xiaopeng Wang, Xisheng Xue, Xingkui Therapeutic Perspectives of CD26 Inhibitors in Imune-Mediated Diseases |
title | Therapeutic Perspectives of CD26 Inhibitors in Imune-Mediated Diseases |
title_full | Therapeutic Perspectives of CD26 Inhibitors in Imune-Mediated Diseases |
title_fullStr | Therapeutic Perspectives of CD26 Inhibitors in Imune-Mediated Diseases |
title_full_unstemmed | Therapeutic Perspectives of CD26 Inhibitors in Imune-Mediated Diseases |
title_short | Therapeutic Perspectives of CD26 Inhibitors in Imune-Mediated Diseases |
title_sort | therapeutic perspectives of cd26 inhibitors in imune-mediated diseases |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9321265/ https://www.ncbi.nlm.nih.gov/pubmed/35889373 http://dx.doi.org/10.3390/molecules27144498 |
work_keys_str_mv | AT huxiaopeng therapeuticperspectivesofcd26inhibitorsinimunemediateddiseases AT wangxisheng therapeuticperspectivesofcd26inhibitorsinimunemediateddiseases AT xuexingkui therapeuticperspectivesofcd26inhibitorsinimunemediateddiseases |